CCO Oncology Podcast - Strategies for Secondary AML and Emerging Therapies for AML

Strategies for Secondary AML and Emerging Therapies for AML

01/10/22 • 15 min

In this podcast episode, Sarah M. Tinsley, PhD, APRN, AOCN, discusses management strategies for secondary AML and novel therapies currently in clinical trials for AML. Topics include:

Liposomal cytarabine plus daunorubicin for secondary AML
An overview of emerging immune-based strategies for AML
Evidence on immune-based therapies, including agents targeting CD47, TIM3, and bispecific antibodies

Presenter:

Sarah M. Tinsley, PhD, APRN, AOCN
Nurse Practitioner
Courtesy Assistant Professor
Department of Malignant Hematology
Moffitt Cancer Center
University of South Florida
Tampa, Florida

In this podcast episode, Sarah M. Tinsley, PhD, APRN, AOCN, discusses management strategies for secondary AML and novel therapies currently in clinical trials for AML. Topics include:

Liposomal cytarabine plus daunorubicin for secondary AML
An overview of emerging immune-based strategies for AML
Evidence on immune-based therapies, including agents targeting CD47, TIM3, and bispecific antibodies

Presenter:

Sarah M. Tinsley, PhD, APRN, AOCN
Nurse Practitioner
Courtesy Assistant Professor
Department of Malignant Hematology
Moffitt Cancer Center
University of South Florida
Tampa, Florida

Previous Episode

An Overview of AML and Treatment Strategies for Patients Unfit for Intensive Therapy

In this podcast episode, Ashley Leak Bryant, PhD, RN, OCN, FAAN, discusses acute myeloid leukemia and management approaches for patients unfit for intensive chemotherapy, with a focus on the nursing perspective. Topics include:

An overview of AML
Identifying patients unfit for intensive therapy
Treatment options for unfit patients including venetoclax combinations
Adverse event profiles of treatment options
Nursing considerations for managing patients with AML unfit for intensive therapy

Presenters:

Ashley Leak Bryant, PhD, RN, OCN, FAAN
Associate Professor
School of Nursing
UNC Lineberger Comprehensive Cancer Center
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Next Episode

Experts Answer Questions on Current and Emerging Options for Hemophilia A Management

In this podcast episode, 3 experts answers questions on the management of hemophilia A from a live webinar. Topics include:

Which patients should have pharmacokinetic-guided therapy?
Toxicities with PEGylated extended half-life products
Factor VIII and bone health
Factor VIII peaks, thrombotic risk, and cardiovascular disease
Choosing between extended half-life products and emicizumab for active patients
Role of fitusiran in the treatment paradigm if approved

Presenters:
Miguel A. Escobar, MD
Professor of Medicine and Pediatrics
Department of Hematology
University of Texas Health Science Center
McGovern Medical School
Director
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas

Mark Reding, MD
Professor of Medicine
Division of Hematology, Oncology, and Transplantation
Director
Center for Bleeding and Clotting Disorders
University of Minnesota
Minneapolis, Minnesota

Guy A. Young, MD
Professor of Pediatrics
Director, Hemostasis and
Thrombosis Center
Children’s Hospital Los Angeles
University of Southern California
Keck School of Medicine
Los Angeles, California

Link to full program, including downloadable slidesets, expert commentary, and on-demand webcast:
https://bit.ly/3zZwP6G